Familial Cancer

, 8:581 | Cite as

Molecular study of CEPBA in familial hematological malignancies

  • R. El Abed
  • V. Bourdon
  • L. Huiart
  • F. Eisinger
  • A. Khelif
  • M. Frenay
  • P. Gesta
  • L. Demange
  • H. Dreyfus
  • V. Bonadona
  • C. Dugast
  • H. Zattara
  • L. Faivre
  • T. Noguchi
  • R. Sauvan
  • Z. Soua
  • H. Sobol
Article

Abstract

Familial aggregation in patients with several haematological malignancies has been described, but the genetic basis for this familial clustering is not known. Few genes predisposing to familial haematological malignancies have been identified, among which RUNX1 and CEBPA have been described as predisposing genes to acute myeloid leukemia (AML). Recent studies on RUNX1 suggest that germline mutations in this gene predispose to a larger panel of familial haematological malignancies than AML. In order to strengthen this hypothesis, we have screened CEBPA for germline mutations in several families presenting aggregation of hematological malignancies (including chronic or acute, lymphoid or myeloid leukemias, Hodgkin’s or non Hodgkin’s lymphomas, and myeloproliferative or myelodysplastic syndromes) with or without solid tumours. Although no deleterious mutations were found, we report two novel and rare variants of uncertain significance. In addition, we confirm that the in frame insertion c.1175_1180dup (p.P194_H195dup) is a germline polymorphism.

Keywords

CEBPA Germline mutation Haematological familial malignancies 

Notes

Acknowledgments

This work was supported by la Société Française d’Hématologie, le Groupe Génétique et Cancer and l’Institut National du Cancer INCa. We would like to thank Dr. Valérie Delague for helpful discussions and all technicians of laboratory for their expert technical assistance.

References

  1. 1.
    Fuchs O (2007) Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias. Folia Biol (Praha) 53(3):97–108Google Scholar
  2. 2.
    Frohling S, Schlenk RF, Stolze I et al (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22(4):624–633CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 94(2):569–574CrossRefPubMedGoogle Scholar
  4. 4.
    Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088–3091CrossRefPubMedGoogle Scholar
  5. 5.
    Fuchs O, Provaznikova D, Kocova M et al (2008) CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin’s lymphoma. Blood Cells Mol Dis 40(3):401–405CrossRefPubMedGoogle Scholar
  6. 6.
    Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351(23):2403–2407CrossRefPubMedGoogle Scholar
  7. 7.
    Nanri T, Uike N, Kawakita T et al (2006) A pedigree harboring a germ-line N-terminal C/EBP{alpha} mutation and development of acute myeloblastic leukemia with a somatic C-terminal C/EBP{alpha} mutation. Blood 108(11):1916Google Scholar
  8. 8.
    Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26(31):5088–5093CrossRefPubMedGoogle Scholar
  9. 9.
    Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19(7):1276–1278CrossRefPubMedGoogle Scholar
  10. 10.
    Renneville A, Mialou V, Philippe N et al (2009) Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23(4):804–806CrossRefPubMedGoogle Scholar
  11. 11.
    Preudhomme C, Renneville A, Bourdon V et al (2009) High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113(22):5583–5587CrossRefPubMedGoogle Scholar
  12. 12.
    Lin LI, Chen CY, Lin DT et al (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379CrossRefPubMedGoogle Scholar
  13. 13.
    Biggio V, Renneville A, Nibourel O et al (2008) Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML. Leukemia 22(3):655–657CrossRefPubMedGoogle Scholar
  14. 14.
    Resende C, Regalo G, Duraes C, Carneiro F, Machado JC (2007) Genetic changes of CEBPA in cancer: mutations or polymorphisms? J Clin Oncol 25(17):2493–2494 (author reply 4–5)CrossRefPubMedGoogle Scholar
  15. 15.
    Wouters BJ, Louwers I, Valk PJ, Lowenberg B, Delwel R (2007) A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood 109(1):389–390CrossRefPubMedGoogle Scholar
  16. 16.
    Fröhling S, Corbacioglu A, Schlenk R, Döhner H, Döhner K (2007) In reply. J Clin Oncol 25(17):2494–2495CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • R. El Abed
    • 1
  • V. Bourdon
    • 2
  • L. Huiart
    • 2
  • F. Eisinger
    • 2
  • A. Khelif
    • 3
  • M. Frenay
    • 4
  • P. Gesta
    • 5
  • L. Demange
    • 6
  • H. Dreyfus
    • 7
  • V. Bonadona
    • 8
  • C. Dugast
    • 9
  • H. Zattara
    • 10
  • L. Faivre
    • 11
  • T. Noguchi
    • 2
  • R. Sauvan
    • 2
  • Z. Soua
    • 1
  • H. Sobol
    • 2
    • 12
  1. 1.Faculté de Médecine, UR Biologie moléculaire des leucémies et lymphomesLaboratoire de BiochimieSousseTunisia
  2. 2.Institut Paoli-Calmettes/CIC Inserm 9502, Département d’Oncologie Génétique, de Prévention et Dépistage/Université d’Aix Marseille II, IPCMarseilleFrance
  3. 3.Service d’Hématologie Clinique, CHU F. HachedSousseTunisia
  4. 4.Centre Antoine LacassagneNiceFrance
  5. 5.CHG NiortNiortFrance
  6. 6.Polyclinique de CourlancyReimsFrance
  7. 7.Institut Ste CatherineAvignonFrance
  8. 8.Unité de génétique Epidémiologique, Centre Léon Bérard LyonLyonFrance
  9. 9.Centre Eugène-MarquisRennesFrance
  10. 10.Département de GénétiqueHôpital de la TimoneMarseilleFrance
  11. 11.Hôpital d’Enfants, CHU de DijonDijonFrance
  12. 12.Université d’Aix Marseille IIMarseilleFrance

Personalised recommendations